

online from January 2009



in vivo

International Journal of Experimental and Clinical
Pathophysiology and Drug Research

Published by the International Institute of Anticancer Research

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iiar-anticancer.org

Selection of Recent Articles

Small Molecule GS-Nitroxide Ameliorates Ionizing Irradiation-Induced Delay in Bone Wound Healing in a Novel Murine Model. A. GOKHALE, J.-C. RWIGEMA, M. EPPERLY, J. GLOWACKI, H. WANG, P. WIPF., J. GOFF, T. DIXON, K. PATRENE, J.S. GREENBERGER (*Pittsburgh, PA; Boston, MA, USA*)

A Non-traumatic *Staphylococcus aureus* Osteomyelitis Model in Pigs. H.E. JENSEN, O.L.NIELSEN, J.S. AGERHOLM, T. IBURG, L.K. JOHANSEN, E. JOHANNESSEN, M. MØLLER, L. JAHN, L. MUNK, B. AALBZ K, P.S. LEIFSSON (*Frederiksberg C, Denmark*)

Effects of Voluntarily Ingested Buprenorphine on Plasma Corticosterone Levels, Body Weight, Water Intake, and Behaviour in Permanently Catheterised Rats. R. GOLDKUHL, J. HAU, K.S.P. ABELSON (*Uppsala, Sweden; Copenhagen, Denmark*)

Pharmacologic Ascorbic Acid Suppresses Syngeneic Tumor Growth and Metastases in Hormone-Refractory Prostate Cancer. H.B. POLLARD, M.A. LEVINE, O. EIDELMAN, M. POLLARD (*Bethesda, MD; Notre Dame, IN, USA*)

Uterus Cryopreservation in the Sheep: One Step Closer to Uterus Transplantation. R. DITTRICH, T. MALTARIS, A. MUELLER, O. STRAHL, I. HOFFMANN, M.W. BECKMANN, P.G. OPPELT (*Erlangen, Germany*)

Modulation of Aged Murine T Lymphocytes *In Vivo* by DPV576-C, a Nanodiamond- and Nanoplatinum-coated Material. M. GHONEUM, A. GHONEUM, L. TOLENTINO, J. GIMZEWSKI (*Los Angeles, CA, USA*)

Twice Weekly Intravenous Treatment of Pancreatic Cancer with Atrial Natriuretic Peptide and Vessel Dilator. A. LENZ, Y. SUN, E.J. EICHELBAUM, W.P. SKELTON, IV, G. PI, D.L. VESELY (*Tampa, FL, USA*)

Successful Anatomic Repair of Fetoscopic Access Sites in the Mid-gestational Rabbit Model using Amnion Cells Engineering. N.A. PAPADOPULOS, D.I. KYRIAKIDIS, U. SCHILLINGER, A. TOTIS, J. HENKE, L. KOVACS, R.E. HORCH, K.T.M. SCHNEIDER, H.-G. MACHENS, E. BIEMER (*Munich; Erlangen, Germany*)

Effects of Fetal Exposure to 4-*n*-octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (*Kagoshima, Japan*)

Comparative Study of Difference Between Long and Short Pulse on Treating Melanoma *In Vivo*. X. CHEN, R.J. SWANSON, K.H. SCHOENBACH, S. ZHENG (*Zhejiang, China; Norfolk, VA, USA*)

Tetrandrine Pre-Treatment has Protective Effects Against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNNA, G. ROSSONI (*Milan, Italy*)

Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUNDAL, K.-M. MYHR, H.I. YLAND (*Bergen, Norway*)

Development of fMRI Tests for Children with Central Auditory Processing Disorders. S. BARTEL-FRIEDRICH, Y. BROECKER, M. KNOERGEN, S. KOESLING (*Halle/Saale, Germany*)

Chronic Hind Limb Ischemia Reduces Myocardial Ischemia-reperfusion Injury in the Rabbit Heart by Promoting Coronary Angiogenesis/Arteriogenesis. V.C. VARNAVAS, K.I. PARASKEVAS, E.K. ILIODROMITIS, A. ZOGA, I. GLAVA, L. KAKLAMANIS, J. SPARTINOS, T. LYRAS, D.T. KREMASTINOS, D.P. MIKHAILIDIS, Z.S. KYRIAKIDES (*Athens, Greece; London, UK*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009) - VOL.7 (2010)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER (*Penzburg, Germany; Vienna, Austria*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Inhibition of c-Jun N-terminal Kinase (JNK) by SP600125 : A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN (*Grenoble, France*)

Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG (*Cardiff, UK; Beijing, China*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, E. CHARKIEWICZ, T. BARTZ, J. BARTEL, D. SCHMIDT, I. GRBAVAC, A. KYRIAKOPOULOS (*Berlin, Germany*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J. AL-RUWAILI, S.E.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, P.A. TOWNSEND, C.L. AUKIM-HASTIE (*Portsmouth; Southampton, UK; Riyadh, Saudi Arabia; Boston, MA, USA*)

Identification of Serpin (α -1-antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.K. ZIGANSHIN, N.Y. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOVA, B.S. AMANDZHOLOV, M.V. KISELEVSKII, T. EFFERTH (*Moscow, Russia; Mainz, Germany*)

DNA-Based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad, Sweden; Mumbai, India*)

Phase II Trial of Adjuvant Chemotherapy with Bi-Weekly Carboplatin Plus Paclitaxel in Patients with Completely Resected Non-small Cell Lung Cancer. M. SUGAYA, H. URAMOTO, A. UCHIYAMA, A. NAGASHIMA, R. NAKANISHI, H. SAKATA, K. NAKANISHI, T. HANAGIRI, K. YASUMOTO (<i>Kitakyushu; Kyushu Kouseinenkin; Iizuka City, Japan</i>)	3039
Hepatic Arterial Infusion with Oxaliplatin, Irinotecan and Doxifluridine for Unresectable Liver Metastases of Colorectal Cancer. Y. CHEN, Z. YAN, J. WANG, X. WANG, J. LUO, Q. LIU (<i>Shanghai, China</i>)	3045
Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results. V. MICHALAKI, S. FOTIOU, S. GENNATAS, C. GENNATAS (<i>Athens, Greece</i>)	3051
Stereotactic Radiosurgery plus Whole-brain Radiotherapy for Treatment of Multiple Metastases from Non-small Cell Lung Cancer. G. MINNITI, M. SALVATI, R. MUNI, G. LANZETTA, M.F. OSTI, E. CLARKE, A. COSTA, A. BOZZAO, G. TRASIMENI, R. MAURIZI ENRICI (<i>Rome; Pozzilli (IS), Italy</i>)	3055
Clinicopathological Features in N0 Oesophageal Cancer Patients. C. KUNISAKI, H. MAKINO, T. OSHIMA, S. FUJII, R. TAKAGAWA, J. KIMURA, T. KOSAKA, H.A. ONO, H. AKIYAMA, I. ENDO (<i>Yokohama, Japan</i>)	3063
Does a New Ultrasound Probe Change the Complication Rates of Transrectal Ultrasound-guided Needle Biopsies of the Prostate? T.H. ECKE, H. GERULLIS, C.J. HEUCK, P. BARTEL, S. HALLMANN, S. KOCH, J. RUTTLOFF (<i>Bad Saarow; Neuss; Essen, Germany; Bronx, NY, USA</i>)	3071
Preliminary Results of Tranilast Treatment for Patients with Advanced Castration-resistant Prostate Cancer. K. IZUMI, A. MIZOKAMI, T. SHIMA, K. NARIMOTO, K. SUGIMOTO, Y. KOBORI, Y. MAEDA, H. KONAKA, E. KOH, M. NAMIKI (<i>Kanazawa; Koshigaya, Japan</i>)	3077
Fine-Needle Aspiration Cytology and ^{99m} Tc-pertechnetate Scintigraphy Together in Patients with Differentiated Thyroid Carcinoma. F. LUMACHI, M. FABBRO, A. TREGNAGHI, L. ANTUNOVIC, F. BUI, D. CECCHIN, P. ZUCCHETTA, A. FASSINA (<i>Padova, Italy</i>)	3083
Vinorelbine plus 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin as Effective Palliative Chemotherapy for Breast Cancer Patients with Acute Disseminated Intravascular Coagulation. P.-H. LIN, Y.-S. LU, C.-H. LIN, D.-Y. CHANG, C.-S. HUANG, A.-L. CHENG, K.-H. YEH (<i>Taipei, Taiwan, ROC</i>)	3087
CCND1 and CDKN1B Polymorphisms and Risk of Breast Cancer. E. CANBAY, I.Y. ERALTAN, A. CERCEL, T. ISBIR, E. GAZIOGLU, F. AYDOGAN, C. CACINA, A. CENGIZ, M. FERAHMAN, E. ZENGIN, H. UNAL (<i>Istanbul, Turkey</i>)	3093
Prognostic Significance of Tumour Marker Index Based on Preoperative CEA and CYFRA 21-1 in Non-small Cell Lung Cancer. M. TOMITA, T. SHIMIZU, T. AYABE, A. YONEI, T. ONITSUKA (<i>Miyazaki, Japan</i>)	3099

* Review (page 2943)

Postoperative External Beam Radiotherapy for Resected Pancreatic Adenocarcinoma: Impact of Chemotherapy on Local Control and Survival. K. OGAWA, H. SHIBUYA, N. UCHIDA, H. ONISHI, Y. OKUNO, M. MYOJIN, M. KOBAYASHI, Y. OGAWA, N. KANESAKA, K. SHIBUYA, S. TOKUMARU, R. SASAMOTO, K. KARASAWA, K. NEMOTO, Y. NISHIMURA, JROSG WORKING SUBGROUP OF GASTROINTESTINAL CANCER (<i>Okinawa; Tokyo; Shimane; Yamanashi; Kobe City; Sapporo; Sendai; Kyoto; Saga; Niigata; Yamagata; Osaka, Japan</i>)	2959
Bevacizumab Combined with Two-weekly Paclitaxel as First-line Therapy for Metastatic Breast Cancer P. KOUNTOURAKIS, D. DOUFEXIS, S. MALIOU, A. KARAGIANNIS, E. KARDARA, C. MARGARI, D. SYKOUTRI, A. TZOVARAS, A. ARDAVANIS (<i>Athens, Greece</i>)	2969
Prognostic Value of Lymphovascular Invasion in Bladder Cancer in Patients Treated with Radical Cystectomy. F. PALMIERI, E. BRUNOCILLA, A. BERTACCINI, M. GUIDI, R. PERNETTI, A.M. MORSELLI-LABATE, G. MARTORANA (<i>Bologna, Italy</i>)	2973
Influence on Busilvex® Pharmacokinetics of Clonazepam Compared to Previous Phenytoin Historical Data. E. CARRERAS, J.Y. CAHN, C. PUOZZO, N. KRÖGER, G. SANZ, A. BUZYN, A. BACIGALUPO, J.P. VERNANT (<i>Bacelona; Valencia, Spain; Grenoble; Toulouse; Paris, France; Hamburg, Germany; Genova, Italy</i>) ..	2977
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type. N. YAMAMOTO, T. YAMANAKA, Y. ICHINOSE, K. KUBOTA, H. SAKAI, A. GEMMA, N. SAIJO, M. FUKUOKA, H. NIITANI (<i>Shizuoka; Fukuoka; Tokyo; Saitama; Osaka, Japan</i>)	2985
Cervical Manifestation of a Borderline Type Ovarian Cancer with Pseudomyxoma Peritonei – A Case Report. R.B. SCHMUCK, K. PIETZNER, A. BUCKENDAHL, J. SCHÖNLEBE, J. SEHOULI (<i>Berlin; Dresden, Germany</i>)	2991
Immunohistochemical Study of Claudin 18 Involvement in Intestinal Differentiation During the Progression of Intraductal Papillary Mucinous Neoplasm. Y. SANADA, Y. HIROSE, S. OSADA, Y. TANAKA, T. TAKAHASHI, K. YAMAGUCHI, K. YOSHIDA (<i>Gifu, Japan</i>)	2995
Successful Right Hepatectomy After Four Treatments of Yttrium-90 Microspheres (SIR-Spheres®) and Concomitant FOLFOX as Bridging Therapy to Resection of Colorectal Liver Metastases. T.C. CHUA, L. BESTER, J. AKTHER, D.L. MORRIS (<i>Sydney, Australia</i>)	3005
Amyloid Deposition in the Tongue: Clinical and Histopathological Profile. F. ANGIERO, R. SERAMONDI, S. MAGISTRO, R. CRIPPA, S. BENEDICENTI, C. RIZZARDI, G. CATTORETTI (<i>Monza; Milan; Genoa; Trieste, Italy</i>)	3009
Metastatic Breast Cancer Presenting as a Primary Hindgut Neuroendocrine Tumour. A.F.C. OKINES, E.A. HAWKES, S. RAO, N. VAN AS, H. MARSH, A. RIDDELL, P.O.G. WILSON, P. OSIN, A.C. WETHERSPOON (<i>London and Surrey, UK</i>)	3015
Protruding and Non-protruding Colon Carcinomas Originating in Gut-associated Lymphoid Tissue. C.A. RUBIO, C. LINDH, J. BJÖRK, H. TÖRNBLOM, R. BEFRITS (<i>Stockholm, Sweden</i>)	3019
Prognostic Evaluation of COX-2 Expression in Renal Cell Carcinoma. M.K. KANKURI-TAMMILEHTO, K.-O. SÖDERSTRÖM, T.-T. PELLINIEMI, T. VAHLBERG, S.O. PYRHÖNEN, E.K. SALMINEN (<i>Turku, Finland</i>)	3023
Phase III Study Comparing Sequential <i>Versus</i> Alternate Administration of Cisplatin-Etoposide and Topotecan as First-line Treatment in Small Cell Lung Cancer. S. BAKA, S. AGELAKI, A. KOTSAKIS, M. VESLEMES, P. PAKOTOULAS, M. AGELIDOU, A. AGELIDOU, E. TSAROUCHA, G. PAVLAKOU, A. GEROGIANNI, N. ANDROULAKIS, L. VAMVAKAS, K. KALBAKIS, D. MAVROUDIS, V. GEORGOULIAS (<i>Athens, Greece</i>)	3031

γ -Tocotrienol Controls Proliferation, Modulates Expression of Cell Cycle Regulatory Proteins and Up-regulates Quinone Reductase NQO2 in MCF-7 Breast Cancer Cells. T.-C. HSIEH, S. ELANGO VAN, J.M. WU (<i>Valhalla, NY, USA</i>).....	2869
The Influence of Cyclin D1 A870G Polymorphism on Colorectal Cancer Risk and Prognosis in a Turkish Population. İ. YAYLIM-ERALTAN, S. ARIKAN, Y. YILDIZ, C. CACINA, H.A. ERGEN, G. TUNA, U. GÖRMÜŞ, Ü. ZEYBEK, T. İSBİR (<i>Istanbul, Turkey</i>)	2875
Induction of Apoptosis by Sphingosine, Sphinganine, and C ₂ -Ceramide in Human Colon Cancer Cells, but not by C ₂ -Dihydroceramide. E.H. AHN, J.J. SCHROEDER (<i>Gyeonggi-do, South Korea; East Lansing, MI, USA</i>).....	2881
Combined Effect of CYP1B1 Codon 432 Polymorphism and N-Acetyltransferase 2 Slow Acetylator Phenotypes in Relation to Breast Cancer in the Turkish Population. Y.K. ÖZBEK, T. ÖZTÜRK, B.M. TÜZÜNER, Z. CALAY, S. ILVAN, F.M. SEYHAN, H.I. KISAKESEN, O. ÖZTÜRK, T. İSBİR (<i>Instabul, Turkey</i>)	2885
The Efficacy of Imiquimod on Dysplastic Lesions of the Oral Mucosa: An Experimental Model. V. GKOU LIONI, A. ELEF THERIADOU, I. YIOTAKIS, E. FER EKIDOU, A. CHRISOVERGIS, A.CH. L. D. KANDILOROS (<i>Athens; Crete, Greece</i>).....	2891
Estrogen Receptors α and β Immunohistochemical Expression: Clinicopathological Correlations in Pituitary Adenomas. B. MANORANJAN, F. SALEHI, B.W. SCHEITHAUER, F. ROTONDO, K. KOVACS, M.D. CUSIMANO (<i>Toronto, ON, Canada; Rochester, MN, USA</i>).....	2897
<i>Clinical Studies</i>	
Docetaxel Second-line Therapy in Patients with Advanced Pancreatic Cancer: A Retrospective Study. M.W. SAIF, K. SYRIGOS, R. PENNEY, K. KALEY (<i>New Haven, CT, USA; Athens, Greece</i>)	2905
Levels of Elevated Circulating Endothelial Cell Decline after Tumor Resection in Patients with Pancreatic Ductal Adenocarcinoma. M.S. SABBAGHIAN, G. ROTHBERGER, A.P. ALONGI, J.-P. GAGNER, J.D. GOLDBERG, L. ROLNITZKY, L. CHIRIBOGA, C.H. HAJDU, D. ZAGZAG, R. BASCH, P. SHAMAMIAN (<i>New York, NY; Charleston, SC, USA</i>)	2911
Zinc- α 2-glycoprotein: A New Biomarker of Breast Cancer? V. DUBOIS, L. DELORT, F. MISHELLANY, T. JARDE, H. BILLARD, C. LEQUEUX, O. DAMOUR, F. PENNAULT-LLORCA, M.P. VASSON, F. CALDEFIE-CHEZET (<i>Clermont-Ferrand; Lyon; Region Lyon Auvergne Rhone-Alpes, France</i>)	2919
Role of Pregabalin in Treatment of Oxaliplatin-induced Sensory Neuropathy. M.W. SAIF, K. SYRIGOS, K. KALEY, I. ISUFI (<i>New Haven, CT, USA; Athens, Greece</i>)	2927
Effects of the Src Inhibitor Saracatinib (AZD0530) on Renal Function in Healthy Subjects. R.N. DALTON, R. CHETTY, M. STUART, R.B. IACONA, A. SWAISLAND (<i>London; Cheshire, UK</i>)	2935
* Short Review: Validation of Blood Testing for <i>K-ras</i> Mutations in Colorectal and Pancreatic Cancer. M. ROGOSNITZKY, R. DANKS (<i>Telz Stone, Israel; Steep, UK</i>)	2943
A 'Hot' Leg: A Rare Case of Isolated Long Bone Metastases from Cervical Cancer. A. DEWDNEY, U. SELVARAJAH (<i>Romford, UK</i>).....	2949
Soluble Carbonic Anhydrase IX Is Not an Independent Prognostic Factor in Human Renal Cell Carcinoma. K. PAPWORTH, J. SANDLUND, K. GRANKVIST, B. LJUNGBERG, T. RASMUSON (<i>Umeå; Stockholm, Sweden</i>).....	2953

PTHrP Regulates Angiogenesis and Bone Resorption via VEGF Expression. S. ISOWA, T. SHIMO, S. IBARAGI, N. KURIO, T. OKUI, K. MATSUBARA, N.M.M. HASSAN, K. KISHIMOTO, A. SASAKI (Okayama; Hiroshima, Japan)	2755
IL-8 and IL-6 Bystander Signalling in Human Glioblastoma Cells Exposed to Gamma Radiation. F. PASI, A. FACOETTI, R. NANO (Pavia, Italy)	2769
Melphalan Modulates the Expression of E7-Specific Biomarkers in E7-Tg Mice. E.J. KIM, H. KIM, S. LEE, J.W. KANG, D.H. LEE, H.S. CHOI, J.M. KIM, Y. YANG, Y.Y. SHEEN, S.N. PARK, D.Y. YOON (Seoul; Daejeon; Sookmyung, Korea)	2773
Cell-free Circulating DNA: Diagnostic Value in Patients with Renal Cell Cancer. S. HAUSER, T. ZAHALKA, J. ELLINGER, G. FECHNER, L.C. HEUKAMP, A. VON RUECKER, S.C. MÜLLER, P.J. BASTIAN (Bonn; Munich, Germany)	2785
Role of Caspases and CD95/Fas in the Apoptotic Effects of a Nucleotide Analog PMEG in CCRF-CEM Cells. H. MERTLÍKOVÁ-KAISEROVÁ, I. VOTRUBA, M. MATOUŠOVÁ, A. HOLÝ, M. HÁJEK (Prague, Czech Republic)	2791
Expression of p27, p21 ^{WAF/Cip1} , and p16 ^{INK4a} in Normal Oral Epithelium, Oral Squamous Papilloma, and Oral Squamous Cell Carcinoma. A.B. QUEIROZ, G. FOCCHI, C. DOBO, T.S. GOMES, D.A. RIBEIRO, C.T.F. OSHIMA (Sao Paulo, SP, Brazil)	2799
Analysis of Chemotherapeutic Response Heterogeneity and Drug Clustering Based on Mechanism of Action Using an <i>In Vitro</i> Assay. S.D. RICE, J.M. HEINZMAN, S.L. BROWER, P.R. ERVIN, N. SONG, K. SHEN, D. WANG (Pittsburgh, PA 15203, USA)	2805
Antiangiogenic Activities and Cisplatin-combined Antitumor Activities of BPR0L075. C.-P. CHEN, C.-B. HU, K.-C. YEH, J.-S. SONG, T.-K. YEH, F.-F. TUNG, L.-L. HWANG, H.-Y. TSENG, Y.-C. HUANG, H.-S. SHY, S.-H. HSIEH, C.-C. SHEN, H.-S. WANG, H.-P. HSIEH, J.-P. LIOU, Y.-S. CHAO, C.-T. CHEN (Miaoli; Taipei, Taiwan, ROC)	2813
A ₃ Adenosine Receptor Antagonist, Truncated Thio-CI-IB-MECA, Induces Apoptosis in T24 Human Bladder Cancer Cells. H. KIM, J.W. KANG, S. LEE, W.J. CHOI, L.S. JEONG, Y. YANG, J. TAE HONG, D.Y. YOON (Seoul; Cheongju, South Korea)	2823
Hypoxia and Activated VEGF/Receptor Pathway in Multiple Myeloma. A. GIATROMANOLAKI, M. BAI, D. MARGARITIS, K.L. BOURANTAS, M.I. KOUKOURAKIS, E. SIVRIDIS, K.C. GATTER (Alexandroupolis; Ioannina, Greece; Oxford, UK)	2831
Immunohistochemical Analysis for Expression of Calpain 1, Calpain 2 and Calpastatin in Endometrial Cancer. D. SALEHIN, I. FROMBERG, C. HAUGK, B. DOHMEN, T. GEORG, R.M. BOHLE, D. BAUERSCHLAG, N. MAASS, M. FRIEDRICH (Krefeld; Kaiserslautern; Homburg/Saar; Aachen, Germany)	2837
Expression of Ki-67 Antigen and Caspase-3 Protein in Benign Lesions and Esophageal Carcinoma. M. FERREIRA BELLINI, P.M. CURY, A.E. SILVA (São José do Rio Preto, SP, Brazil)	2845
Curcumin Alters the Migratory Phenotype of Nasopharyngeal Carcinoma Cells through Up-regulation of E-Cadherin. T.-S. WONG, W.-S. CHAN, C.-H. LI, R.W.-M. LIU, W.W.-Y. TANG, S.-W. TSAO, R.K.-Y. TSANG, W.-K. HO, W.I. WEI, J.Y.-W. CHAN (Hong Kong, China)	2851
Heterogeneity of Radiation- and TNF-alpha-induced Programmed Cell Death in Carcinoma, Sarcoma and Lymphoma Cell Lines. T. BÖLLING, A. KOLKMEYER, B. GREVE, I. ERNST, N. WILLICH, S. KÖNEMANN (Münster, Germany)	2857
Carbonyl Cyanide <i>P</i> -(Trifluoromethoxy) Phenylhydroazone Induces Caspase-independent Apoptosis in As4.1 Juxtglomerular Cells. Y.H. HAN, Y.M. YANG, W.H. PARK (JeonJu, Republic of Korea)	2863